Average buy price is hidden here because at least one covered purchase quarter has no usable local mean price.
| Quarter | Action | Shares change | Est. value change | Δ Own | Shares held | Filing date |
|---|---|---|---|---|---|---|
| Q1 2026 | Added | +12K | – | +36.5% | 45K | May 15, 2026 |
| Q4 2025 | Reduced | −405 | – | −1.2% | 33K | Feb 17, 2026 |
| Q3 2025 | Reduced | −9K | – | −20.9% | 33K | Nov 14, 2025 |
| Q2 2025 | Reduced | −1K | – | −2.3% | 42K | Aug 14, 2025 |
| Q1 2025 | Reduced | −22K | – | −33.5% | 43K | May 15, 2025 |
| Q4 2024 | Reduced | −26K | – | −28.6% | 65K | Feb 14, 2025 |
| Q3 2024 | Added | +62K | – | +214.3% | 91K | Nov 14, 2024 |
| Q2 2024 | Added | +15K | – | +113.6% | 29K | Aug 14, 2024 |
| Q1 2024 | Reduced | −8K | – | −37.7% | 14K | May 15, 2024 |
| Q4 2023 | Reduced | −589 | – | −2.6% | 22K | Feb 14, 2024 |
| Q3 2023 | Added | +3K | – | +16.8% | 22K | Nov 14, 2023 |
| Q2 2023 | Reduced | −11K | – | −37.2% | 19K | Aug 14, 2023 |
| Q1 2023 | New | +30K | – | – | 30K | May 15, 2023 |
| Q3 2022 | Added | +1K | – | +27.5% | 5K | Nov 14, 2022 |
| Q2 2022 | Reduced | −3K | – | −38.8% | 4K | Aug 15, 2022 |
| Q1 2022 | Reduced | −18K | – | −73.5% | 7K | May 16, 2022 |
| Q4 2021 | Added | +4K | – | +20.6% | 25K | Feb 14, 2022 |
| Q3 2021 | Added | +13K | – | +168.7% | 20K | Nov 15, 2021 |
| Q2 2021 | Added | +301 | – | +4.1% | 8K | Aug 16, 2021 |
| Q1 2021 | First covered | – | – | – | 7K | May 17, 2021 |
Yes. As of Q1 2026, Joel Greenblatt disclosed 45K shares of PCRX, worth an amount we cannot price. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Joel Greenblatt held PCRX since at least Q1 2021, when this filing coverage begins; the opening snapshot is not a disclosed purchase. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
The quarter-by-quarter table above shows each sale and reduction Joel Greenblatt disclosed in PCRX. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Joel Greenblatt disclosed 45K shares of PCRX as of Q1 2026. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Joel Greenblatt began building the PCRX position before our 13F history starts, so an exact average buy price cannot be estimated without understating it. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
13F filings disclose quarter-end holdings, not trade dates or execution prices. These estimates use each covered quarter's average market price; the add average excludes the opening position and quarters without price data. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
